Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib vs Sorafenib in Advanced HCC
NCT00881751Phase 2Completed
- Sponsor
- Medical University of South Carolina
- Start
- Mar 2009
- Primary completion
- May 2016
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and erlotinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Medical University of South Carolina. Primary endpoint: Overall Survival. Started Mar 2009; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00881751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881751.